Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us

  • Exchange: Frankfurt
  • Sector: Health Care
  • Industry: Biotech & Pharma
  • Sub-Industry: Specialty Pharma

Veloxis Pharmaceuticals A/S

+ Add to Watchlist

L8H:GR

0.107 EUR 0.063 37.06%

As of 02:08:45 ET on 03/04/2015.

Snapshot for Veloxis Pharmaceuticals A/S (L8H)

Open: 0.121 Day's Range: 0.107 - 0.121 Volume: 10,000
Previous Close: 0.170 52wk Range: 0.063 - 0.316 1-Yr Rtn: +69.84%

Stock Chart for L8H

No chart data available.
  • L8H:GR 0.107
  • 1M
  • 1Y
0.170
Interactive L8H Chart

Previous Close

No chart data available.
Interactive Chart
  • 1W
  • 1M
  • YTD
  • 1Y
  • 3Y
  • 5Y
Close:
Open:
High:
Low:
Volume:
Recently Viewed Symbols
Save as Watchlist
Saving as watchlist...

Key Statistics for L8H

Current P/E Ratio (ttm) -
Estimated P/E(12/2015) -
Relative P/E vs. DAX -
Earnings Per Share (DKK) (ttm) -
Est. EPS (DKK) (12/2015) -0.0650
Est. PEG Ratio -
Market Cap (M EUR) 282.71
Shares Outstanding (M) 1,663.00
30 Day Average Volume 3,020
Price/Book (mrq) -
Price/Sale (ttm) -
Dividend Indicated Gross Yield -%
Cash Dividend -
Dividend Ex-Date
5 Year Dividend Growth -
Next Earnings Announcement 05/20/2015
mrq = Most Recent Quarter; ttm = Trailing Twelve Months

Income Statement for L8H

  • Revenue
  • Net Income (M/DKK)
  • Profit Margin (%)

Company Profile & Key Executives for L8H

Veloxis Pharmaceuticals A/S is a specialty pharmaceutical company. The Company has numerous products in clinical stage and developed products, including a drug for immunosuppression, specifically organ transplantation, and products to combat certain cardiovascular diseases.

William J PolvinoPresident/CEOJohnny StilouExecutive VP/CFO
John D WeinbergExecutive VP/CCOChristina SylvestSVP:Global Clinical Dev&Operat
More Company Profile & Key Executives for L8H

Quotes delayed, except where indicated otherwise. All prices in local currency. Time is ET.

Sponsored Link
Advertisement
Advertisement
Sponsored Links
Advertisements
sec ||= nil